Other financial assets
|
Loans
associates and joint ventures |
Other
participating interests |
Other
receivables |
Other
deferred items |
Total
|
|
|
Balance at 1 January 2017
|
253
|
50
|
136
|
24
|
463
|
|---|---|---|---|---|---|
|
Changes:
|
|||||
|
- Charged to the income statement
|
12
|
(8)
|
31
|
(6)
|
29
|
|
- Acquisitions
|
-
|
7
|
18
|
2
|
27
|
|
- Capital payments
|
-
|
47
|
-
|
-
|
47
|
|
- Disposals
|
-
|
(3)
|
-
|
-
|
(3)
|
|
- Loans granted / prepayments
|
-
|
-
|
49
|
-
|
49
|
|
- Repayments
|
(65)
|
-
|
(47)
|
-
|
(112)
|
|
- Other consolidation changes
|
(2)
|
-
|
-
|
-
|
(2)
|
|
- Exchange differences
|
(4)
|
(4)
|
(9)
|
(1)
|
(18)
|
|
- Transfers
|
(1)
|
1
|
(2)
|
-
|
(2)
|
|
- Changes in fair value
|
-
|
(1)
|
-
|
-
|
(1)
|
|
- Other
|
-
|
-
|
1
|
(3)
|
(2)
|
|
Balance at 31 December 2017
|
193
|
89
|
177
|
16
|
475
|
|
Changes:
|
|||||
|
- Charged to the income statement
|
-
|
-
|
(29)
|
(5)
|
(34)
|
|
- Acquisitions
|
-
|
-
|
(13)
|
(1)
|
(14)
|
|
- Capital payments
|
-
|
22
|
-
|
-
|
22
|
|
- Loans granted / prepayments
|
8
|
-
|
2
|
-
|
10
|
|
- Repayments
|
(175)
|
-
|
(29)
|
5
|
(199)
|
|
- Other consolidation changes
|
-
|
-
|
-
|
(6)
|
(6)
|
|
- Exchange differences
|
-
|
-
|
(1)
|
-
|
(1)
|
|
- Transfers
|
(24)
|
-
|
(18)
|
-
|
(42)
|
|
- Changes in fair value
|
-
|
16
|
-
|
-
|
16
|
|
- Other
|
-
|
37
|
(1)
|
-
|
36
|
|
Balance at 31 December 2018
|
2
|
164
|
88
|
9
|
263
|
Other participating interests relate to equity instruments in companies whose activities support DSM's business and which can be quoted or unquoted. In view of the adoption of IFRS 9 Financial Instruments as of January 2018, DSM revalued the Other participating interests which were not yet recognized at fair value. The adoption of this standard has not resulted in a significant impact on the financial information. See Note 23 Financial instruments and risks for the fair value hierarchy.
Repayments to the value of €192 million relate to the settlement of various loans and the financing of ChemicaInvest. See also Note 10 Associates and joint arrangements.
Transfers mainly relate to the reclassification to current assets.
Other includes the earn-out relating to the sale of DSM Sinochem Pharmaceuticals. See Note 10 Associates and joint arrangements.